Medifast (MED) EBITDA (2010 - 2026)

Medifast has reported EBITDA for 17 years, with the latest figure at -$3.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 161.09% year-over-year to -$3.3 million; the trailing twelve-month figure through Mar 2026 stood at -$16.2 million (down 156.92% YoY), and the FY2025 full-year result was -$14.2 million, down 593.85% from the prior year.
• EBITDA for Q1 2026 stood at -$3.3 million, up from -$7.8 million in the prior quarter.
• The five-year high for EBITDA was $55.1 million in Q1 2022, with the low at -$7.9 million in Q2 2024.
• Historically, EBITDA has averaged $17.4 million across 5 years, with a median of $7.9 million in 2024.
• The largest YoY upside for EBITDA was 86.47% in 2025 against a maximum downside of 1200.56% in 2025.
• Medifast's EBITDA stood at $32.6 million in 2022, then slumped by 73.39% to $8.7 million in 2023, then tumbled by 91.83% to $709000.0 in 2024, then sank by 1200.56% to -$7.8 million in 2025, then soared by 57.77% to -$3.3 million in 2026.
• The last three EBITDA figures came in at -$3.3 million (Q1 2026), -$7.8 million (Q4 2025), and -$4.1 million (Q3 2025), per Business Quant data.